Noetic Fund
Noetic Fund, established in 2021 and based in Toronto, Canada, is a venture capital firm focused on investing in emerging and early-stage companies within the wellness, therapeutic, and pharmaceutical sectors globally. The fund emphasizes the advancement of mental, emotional, psychological, and physical health through its investments in alternative therapies, digital health, molecular therapeutics, medical devices, and wellness technologies. Noetic Fund is committed to fostering scientific innovation that enhances the human experience, particularly addressing issues related to mental health and central nervous system complications. The firm is guided by the North Star pledge, underscoring its dedication to responsible stewardship in the health sector.
Apollo Neuroscience, Inc. is a Pittsburgh-based company that specializes in manufacturing a wearable wellness device designed to aid recovery from chronic stress through gentle vibrations. The device is complemented by an application that leverages neuroscience and machine learning to enhance heart rate variability, assisting users in various activities such as waking up, focusing, unwinding, and improving parasympathetic nervous system function. Founded in 2016, Apollo's products are marketed online and are intended to promote overall wellness rather than treat psychiatric disorders. The company emphasizes that its offerings are not substitutes for professional medical care.
CaaMTech, Inc. is a drug discovery and optimization company based in Issaquah, Washington, established in 2019. The company specializes in engineering psychedelic drugs, focusing on the creation and optimization of psychedelic compounds and formulations. CaaMTech employs rigorous scientific methods and continuous innovation to develop psychedelic medicines aimed at treating various conditions, including depression and PTSD. Additionally, the company offers drug safety and efficacy screening services, contributing to the health industry's understanding and use of psychedelic therapies.
Sana Health UK Limited develops a sleep mask for people with severe sleep problems caused by high anxiety or pain. The company offers Sana, a wearable device that allows the wearer to put themselves to sleep in 10 minutes. Its mask measures and tracks user’s overall state of health and vitality over time, and uses this measure to tailor the device to get user to deep relaxation and sleep fast. Sana Health UK Limited was founded in 2015 and is based in Dorchester, United Kingdom.
Apollo Neuroscience, Inc. is a Pittsburgh-based company that specializes in manufacturing a wearable wellness device designed to aid recovery from chronic stress through gentle vibrations. The device is complemented by an application that leverages neuroscience and machine learning to enhance heart rate variability, assisting users in various activities such as waking up, focusing, unwinding, and improving parasympathetic nervous system function. Founded in 2016, Apollo's products are marketed online and are intended to promote overall wellness rather than treat psychiatric disorders. The company emphasizes that its offerings are not substitutes for professional medical care.
Operator of a care platform intended to build an ecosystem for psychedelic models of care. The company's platform focuses on psychedelic therapeutics and builds, backs, and incubates best-in-class companies and brings extensive operational and strategic expertise to tackling the mental illness epidemic, enabling users to drive profitable and scalable mental health outcomes across the entire treatment arc from diagnosis.
Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York, founded in 2019. The company specializes in developing innovative psychotropic drugs aimed at treating various neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. Gilgamesh focuses on creating novel chemical entities through a blend of medicinal chemistry, neuroscience, and drug development expertise. By leveraging its unique approach, the company aims to provide effective therapies that enhance recovery for patients dealing with central nervous system disorders.
Bexson Biomedical is focused on creating an innovative formulation of ketamine specifically designed for the treatment of chronic and acute pain disorders. The company is developing a subcutaneous ketamine delivery system that aims to overcome the limitations of existing ketamine preparations, particularly in terms of controlling overdosing and minimizing the need for patient monitoring. Their lead product features a unique formulation of ketamine that is administered through a minimally invasive, wearable, subcutaneous infusion pump. This approach enables healthcare providers to more effectively manage pain in patients, enhancing treatment outcomes while addressing safety concerns associated with traditional ketamine therapies.
Beckley Psytech Limited manufactures psychedelic drug for treating psychiatric and neurological diseases. Beckley Psytech Limited was formerly known as Beckley Psychedelics Limited and changed its name to Beckley Psytech Limited in May 2020. The company was founded in 2014 and is based in Oxford, United Kingdom.
Cybin is a biopharmaceutical company dedicated to developing safe and effective therapeutics using psychedelic and medicinal mushrooms. The company focuses on creating psilocybin-based products in regions where such substances are permitted, while also conducting clinical studies across North America and other areas through collaborations with academic and institutional partners. Cybin's efforts encompass the advancement of psychedelic-based therapies, innovative delivery mechanisms, and the development of novel compounds aimed at addressing a range of mental health issues, including various psychiatric and neurological conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.